Enhancer	O
invasion	O
shapes	O
MYCN	S-GENE
-	O
dependent	O
transcriptional	O
amplification	O
in	O
neuroblastoma	O
.	O


Amplification	O
of	O
the	O
locus	O
encoding	O
the	O
oncogenic	O
transcription	O
factor	O
MYCN	S-GENE
is	O
a	O
defining	O
feature	O
of	O
high	O
-	O
risk	O
neuroblastoma	O
.	O


Here	O
we	O
present	O
the	O
first	O
dynamic	O
chromatin	O
and	O
transcriptional	O
landscape	O
of	O
MYCN	S-GENE
perturbation	O
in	O
neuroblastoma	O
.	O


At	O
oncogenic	O
levels	O
,	O
MYCN	S-GENE
associates	O
with	O
E	O
-	O
box	O
binding	O
motifs	O
in	O
an	O
affinity	O
-	O
dependent	O
manner	O
,	O
binding	O
to	O
strong	O
canonical	O
E	O
-	O
boxes	O
at	O
promoters	O
and	O
invading	O
abundant	O
weaker	O
non	O
-	O
canonical	O
E	O
-	O
boxes	O
clustered	O
at	O
enhancers	O
.	O


Loss	O
of	O
MYCN	S-GENE
leads	O
to	O
a	O
global	O
reduction	O
in	O
transcription	O
,	O
which	O
is	O
most	O
pronounced	O
at	O
MYCN	S-GENE
target	O
genes	O
with	O
the	O
greatest	O
enhancer	O
occupancy	O
.	O


These	O
highly	O
occupied	O
MYCN	S-GENE
target	O
genes	O
show	O
tissue	O
-	O
specific	O
expression	O
and	O
are	O
linked	O
to	O
poor	O
patient	O
survival	O
.	O


The	O
activity	O
of	O
genes	O
with	O
MYCN	S-GENE
-	O
occupied	O
enhancers	O
is	O
dependent	O
on	O
the	O
tissue	O
-	O
specific	O
transcription	O
factor	O
TWIST1	S-GENE
,	O
which	O
co	O
-	O
occupies	O
enhancers	O
with	O
MYCN	S-GENE
and	O
is	O
required	O
for	O
MYCN	S-GENE
-	O
dependent	O
proliferation	O
.	O


These	O
data	O
implicate	O
tissue	O
-	O
specific	O
enhancers	O
in	O
defining	O
often	O
highly	O
tumor	O
-	O
specific	O
'	O
MYC	S-GENE
target	O
gene	O
signatures	O
'	O
and	O
identify	O
disruption	O
of	O
the	O
MYCN	S-GENE
enhancer	O
regulatory	O
axis	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
in	O
neuroblastoma	O
.	O
